Inclusion on the list of medicines approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit is substantial.
Clinical Added Value
important
In view of the results obtained in a population with an unfavourable prognosis and the size of the effect observed, the Transparency Committee considers that TORISEL provides a substantial improvement in actual benefit (IAB level II) compared with interferon alpha (ROFERON-A) in advanced renal cell carcinoma patients with at least 3 of the 6 prognostic risk factors.
Listen
